Amgen
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Drug Manufacturers - General
業務概覽 Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introducedits first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgenalso has a growing biosimilar portfolio.
公司地址 One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
電話號碼 +1 805 447-1000
傳真號碼 +1 805 447-1010
公司網頁 https://www.amgen.com
員工數量 31500
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Robert A. Bradway Chairman of the Board, President and Chief Executive Officer 美元 1.87M 13/02/2026
Mr. Jonathan P. Graham Executive Vice President, General Counsel and Secretary -- 13/02/2026
Mr. Murdo Gordon Executive Vice President, Global Commercial Operations 美元 1.20M 13/02/2026
Mr. Esteban Santos Executive Vice President, Operations -- 13/02/2026
Mr. Matthew C. Busch Vice President, Finance and Chief Accounting Officer -- 13/02/2026
Dr. David M. Reese, M.D. Executive Vice President and Chief Technology Officer 美元 1.27M 13/02/2026
Mr. Peter H. Griffith Executive Vice President and Chief Financial Officer 美元 1.13M 13/02/2026
Ms. Nancy A. Grygiel Senior Vice President and Chief Compliance Officer -- 13/02/2026
Mr. Derek Miller Senior Vice President, Human Resources -- 13/02/2026
Dr. James E. Bradner, M.D. Executive Vice President, Research and Development 美元 1.21M 13/02/2026
Ms. Rachna Khosla Senior Vice President, Business Development -- 13/02/2026
 
董事會成員
董事會 職務 更新日期
Ms. Amy E. Miles Independent Director 13/02/2026
Mr. Charles M. Holley, Jr Independent Director 13/02/2026
Ms. Ellen J. Kullman Independent Director 13/02/2026
Mr. Robert A. Eckert Lead Independent Director 13/02/2026
Mr. Robert A. Bradway Chairman of the Board, President and Chief Executive Officer 13/02/2026
Professor Dr. Tyler E. Jacks, PhD Independent Director 13/02/2026
Mr. Greg C. Garland Independent Director 13/02/2026
Dr. Wanda M. Austin Independent Director 13/02/2026
Dr. Brian J. Druker, M.D. Independent Director 13/02/2026
Mr. Michael V. Drake Independent Director 13/02/2026
Dr. S. Omar Ishrak Independent Director 13/02/2026
Ms. Mary E. Klotman Independent Director 13/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:24)
代號 名稱 佔比% ▼ 持有日期
SDGiShares MSCI Global Sust Dev Goals ETF<0.000001%27/02/2026
SGLCSGI U.S. Large Cap Core ETF<0.000001%30/09/2025
SHRTGotham Short Strategies ETF<0.000001%28/01/2026
SIXAETC 6 Meridian Mega Cap Equity ETF<0.000001%04/02/2026
SIXHETC 6 Meridian Hdg Eq-Idx Opt Strat ETF<0.000001%04/02/2026
SPHDInvesco S&P 500® High Div Low Vol ETF<0.000001%03/02/2026
SPUSSP Funds S&P 500 Sharia Industry Ex ETF<0.000001%27/02/2026
SPXMAzoria 500 Meritocracy ETF<0.000001%09/12/2025
SQEWLeaderShares® Equity Skew ETF<0.000001%20/10/2025
STNCHennessy Sustainable ETF<0.000001%03/10/2025
SZNEPacer CFRA-Stovall Eq WghtSeasnlRottnETF<0.000001%27/02/2026
THWabrdn World Healthcare<0.000001%31/07/2025
TIMEClockwise U.S. Core Equity ETF<0.000001%13/08/2025
TMFEMotley Fool Capital Efficiency 100 ETF<0.000001%27/02/2026
USLBInvesco Russell 1000 Low Beta Eq Wt ETF<0.000001%20/03/2023
USXFiShares® ESG Advanced MSCI USA ETF<0.000001%28/02/2026
VSMVVictoryShares US Mult-Fctr Mnmm Vltl ETF<0.000001%20/10/2025
WBIGWBI BullBear Yield 3000 ETF<0.000001%20/11/2025
WRNDNYLI Global Equity R&D Leaders ETF<0.000001%28/08/2025
WSGEWarren Street Global Equity ETF<0.000001%07/01/2026
  1    2    3    4    5    6    7    8    9    10    11    12    13    14    15    16    17    18    19    20   21    22  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.